Clinical trial NCT00715676 - References

Osteoporosis — Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density

Citation(s)

•   Ke HZ, Qi H, Crawford DT, Simmons HA, Xu G, Li M, Plum L, Clagett-Dame M, DeLuca HF, Thompson DD, Brown TA
  A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J Bone Miner Res. 2005 Oct;20(10):1742-55. Epub 2005 Jun 13.
•   Plum LA, Fitzpatrick LA, Ma X, Binkley NC, Zella JB, Clagett-Dame M, DeLuca HF
  2MD, a new anabolic agent for osteoporosis treatment. Osteoporos Int. 2006;17(5):704-15. Epub 2006 Feb 21.
•   Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF
  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13487-91. Epub 2002 Oct 8.

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Daily-dose, Proof-of-concept Study of a Vitamin D Compound in Postmenopausal Women With Osteopenia

Details for clinical trial NCT00715676